All Posts By

Smartkarma Daily Briefs

Daily Brief Industrials: Tenneco Clean Air India Ltd, Transformers & Rectifiers (India) Ltd, Srg Takamiya, Sanyo Trading, Leonardo DRS , MARUKA FURUSATO , Regal Rexnord , Ametek Inc and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Tenneco Clean Air India Ltd IPO – No Adrenaline Rush Here
  • Tenneco Clean Air India Ltd IPO: Stagnated Topline, Increased Profits, At A Discount
  • Transformers & Rectifiers (India) Ltd: Governance Jolt, Operational Pause—but Fundamentals Intact
  • Full Report: Takamiya (2445 JP) – September 19, 2025
  • Primer: Tenneco Clean Air India Ltd (1880671D IN) – Nov 2025
  • Sanyo Trading (3176 JP): Full-year FY09/25 flash update
  • Leonardo DRS Expands in Naval Power—Is Asia the Next Multibillion-Dollar Frontier?
  • MARUKA FURUSATO (7128 JP): Q3 FY12/25 flash update
  • Regal Rexnord: An Insight Into Its Commercial & Residential HVAC Performance & Key Growth Levers!
  • Inside AMETEK’s Recent Expansion: Will Automation & Engineered Solutions Keep the Momentum Alive?


Tenneco Clean Air India Ltd IPO – No Adrenaline Rush Here

By Sreemant Dudhoria,CFA

  • We present five reasons why there is no adrenaline rush for Tenneco Clean Air India Ltd (1880671D IN) ‘s IPO
  • IPO is a complete offer for sale of USD 406 million. There is no fresh issue of equity.
  • At 24x P/E on Q1FY26 annualized earnings, the IPO valuation appears fair.

Tenneco Clean Air India Ltd IPO: Stagnated Topline, Increased Profits, At A Discount

By Hong Jie Seow

  • Tenneco Clean Air India Ltd (1880671D IN)  is now looking to raise up to US$406m in its upcoming India IPO.
  • TCAIL designs and manufactures clean air, powertrain, and suspension solutions for Indian OEMs, export markets, and the aftermarket, serving PVs, CVs, OHs, and industrial applications.
  • We have looked at the company’s past performance in our earlier notes. In this note, we talk about the RHP updates and valuations.

Transformers & Rectifiers (India) Ltd: Governance Jolt, Operational Pause—but Fundamentals Intact

By Sudarshan Bhandari

  • World Bank debarred TARIL from participating in its funded projects following old Nigerian contract issues; the company contests it.
  • The incident has raised governance questions and led to an exaggerated stock sell-off, despite immaterial financial exposure and reaffirmed guidance. 
  • Debarment is isolated and non-material. Execution delays are transitory. Strong order book, backward integration, and FY26 guidance make TARIL attractive on dips.

Full Report: Takamiya (2445 JP) – September 19, 2025

By Sessa Investment Research

  • Takamiya (hereafter, the Company) is a leading manufacturer of temporary equipment used at construction sites, with its business centered on the next-generation scaffolding system Iq System, launched in 2014.
  • Its vision is to become the industry’s first scaffolding platform company, shifting from a flow-based to a stock-based business centered on the Takamiya Platform, with the aim of establishing a new profit structure and strengthening the balance sheet.
  • Construction investment continues to trend upward, and construction volume among the Company’s customers remains resilient.

Primer: Tenneco Clean Air India Ltd (1880671D IN) – Nov 2025

By αSK

  • Tenneco Clean Air India Ltd. is a leading Tier-I automotive component supplier in India with strong market positions in clean air and advanced ride technologies, poised to benefit from stricter emission norms and premiumization trends.
  • The company has demonstrated robust profitability improvement through effective cost management, despite a recent decline in topline revenue, particularly in its clean air segment.
  • The upcoming IPO is a 100% Offer for Sale by the promoter, which will not infuse capital into the company but aims to enhance visibility and provide a public market for its shares.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Sanyo Trading (3176 JP): Full-year FY09/25 flash update

By Shared Research

  • Sanyo Trading’s FY09/25 sales rose 2.7% YoY to JPY132.7bn, driven by strong Sustainability segment sales.
  • Operating profit fell 9.1% YoY to JPY6.4bn due to higher SG&A expenses and investment valuation losses.
  • FY09/26 forecasts project a 2.0% YoY sales decline to JPY130.0bn, with profit decreases at all levels.

Leonardo DRS Expands in Naval Power—Is Asia the Next Multibillion-Dollar Frontier?

By Baptista Research

  • Leonardo DRS, in its third quarter fiscal year 2025 performance, displayed resilience and robust growth trends that highlight both the opportunities and challenges faced by the company.
  • The company reported strong bookings and backlog figures, aligning closely with evolving customer priorities, particularly in areas such as counter unmanned aerial systems (UAS), advanced infrared sensing, naval network computing, and electric power and propulsion technologies.
  • Bookings for the quarter reached $1.3 billion, contributing to a book-to-bill ratio of 1.4x, with the total backlog elevating to $8.9 billion, an 8% year-over-year increase.

MARUKA FURUSATO (7128 JP): Q3 FY12/25 flash update

By Shared Research

  • Revenue for cumulative Q3 FY12/25 declined YoY, with Machinery & Tools and Construction Machinery segments showing decreased revenue and profit.
  • Domestic machinery sector revenue fell 9.7% YoY, while overseas revenue increased 2.1% YoY, with mixed regional performance.
  • Steel construction materials sector revenue decreased 5.8% YoY, while housing equipment sector revenue grew 9.7% YoY.

Regal Rexnord: An Insight Into Its Commercial & Residential HVAC Performance & Key Growth Levers!

By Baptista Research

  • Regal Rexnord’s third quarter performance for 2025 was marked by some notable achievements and challenges.
  • The company reported a 2% increase in sales and a 10% rise in orders, signaling a positive momentum in their operations.
  • However, their adjusted gross margin decreased by 80 basis points due to unfavorable product mix and pressures from increased tariffs and rare earth magnet supply constraints.

Inside AMETEK’s Recent Expansion: Will Automation & Engineered Solutions Keep the Momentum Alive?

By Baptista Research

  • AMETEK, Inc. demonstrated robust performance during the third quarter of 2025, marked by noteworthy achievements across various financial metrics.
  • The company announced double-digit growth in key areas such as sales, orders, operating profit, and diluted earnings per share.
  • The quarter recorded a historical sales figure of $1.89 billion, reflecting an 11% increase compared to the same period in 2024.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Generation Bio , LongBio Pharma (Suzhou), Ce Holdings, Bristol Myers Squibb Co, Gilead Sciences, Merck & Co, Nipro Corp, Oryzon Genomics, Seikagaku Corp, Ship Healthcare Holdings and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Strategic Reviews, Mergers, and Financing Updates: Key Developments in Biopharma, Hospitality
  • Pre-IPO LongBio Pharma (Suzhou) – Thoughts on The Pipeline and The Commercialization Outlook
  • Primer: Ce Holdings (4320 JP) – Nov 2025
  • Bristol-Myers Squibb Is Betting Big on Cobenfy — Could This Be the Next Blockbuster Drug?
  • Gilead Sciences Unveils Game-Changing PrEP Strategy—Inside the Yeztugo Breakthrough!
  • Merck & Co. Enters Retina Race with EyeBio Buy—Is This the Future of Vision Therapy?
  • Nipro Corp (8086 JP): 1H FY03/26 flash update
  • Oryzon Genomics — Progression across the pipeline in Q3
  • Seikagaku Corp (4548 JP): 1H FY03/26 flash update
  • Ship Healthcare Holdings (3360 JP): 1H FY03/26 flash update


Strategic Reviews, Mergers, and Financing Updates: Key Developments in Biopharma, Hospitality

By Special Situation Investments

  • Generation Bio (GBIO) is undergoing a strategic review with potential outcomes including liquidation, reverse merger, or sale, with insiders owning 22%.
  • Sotherly Hotels (SOHOO) is being acquired by two PE firms, with preferred shares trading at a wider spread than common shares.
  • LakeShore Biopharma (LSBCF) signed a definitive privatization agreement at $0.90/share, with closing expected in Q1 2026.

Pre-IPO LongBio Pharma (Suzhou) – Thoughts on The Pipeline and The Commercialization Outlook

By Xinyao (Criss) Wang

  • LP-003’s indications are small if compared with big indications in autoimmune diseases.So, LP-003 needs to demonstrate excellent efficacy. Otherwise, it would face fierce competition from Xolair/biosimilars, leaving limited market space.
  • The core advantage of LP-005 is that multi-target complement inhibitor has superior efficacy potential compared to single-target ones. The downside is the concerns on safety profile and slow R&D progress.
  • Post-Money valuation of LongBio Pharma reached about RMB2 billion after Series C Financing. A comfortable valuation range could be RMB3-5 billion, or about 50%-150% upside from Series C Financing.

Primer: Ce Holdings (4320 JP) – Nov 2025

By αSK

  • Ce Holdings is a specialized provider of medical information systems, primarily Electronic Medical Record (EMR) systems, strategically positioned to capitalize on Japan’s healthcare digitalization trend.
  • The company exhibits a strong growth profile, evidenced by a 3-year net income CAGR of 38.4% and a consistently increasing dividend, supported by favorable demographic tailwinds from Japan’s aging population.
  • Valuation appears attractive, with a P/E ratio of 7.8x, trading at a significant discount to healthcare IT peers, suggesting a potential mispricing given its solid financial performance and market position.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Bristol-Myers Squibb Is Betting Big on Cobenfy — Could This Be the Next Blockbuster Drug?

By Baptista Research

  • Bristol-Myers Squibb’s (BMS) Q3 2025 results reflect a mixed performance, characterized by robust growth in its new portfolio and strategic shifts, but also by challenges from legacy products.
  • The company’s growth portfolio demonstrated strong sales, with a 17% increase year-over-year.
  • Growth was primarily driven by their immuno-oncology (IO) products, Reblozyl, Camzyos, and Breyanzi.

Gilead Sciences Unveils Game-Changing PrEP Strategy—Inside the Yeztugo Breakthrough!

By Baptista Research

  • Gilead Sciences’ third quarter of 2025 results demonstrate mixed performance across the company’s diverse portfolio, characterized by both significant growth in certain segments and challenges in others.
  • The HIV therapy segment remains a stronghold for Gilead, seeing expanding revenues with products like Biktarvy and Descovy demonstrating year-over-year growth of 6% and 20%, respectively.
  • Notably, Biktarvy achieved a record U.S. market share, highlighting robust demand driven by the company’s commercial execution.

Merck & Co. Enters Retina Race with EyeBio Buy—Is This the Future of Vision Therapy?

By Baptista Research

  • Merck & Co., Inc.’s third-quarter performance demonstrates its commitment to leveraging scientific advances to deliver value in the healthcare space.
  • The company’s revenue for the quarter reached $17.3 billion, a growth of 4% despite foreign exchange headwinds.
  • This growth was primarily driven by the continued strength of its oncology segment, notably the drug KEYTRUDA, which saw an 8% increase in sales, contributing $8.1 billion.

Nipro Corp (8086 JP): 1H FY03/26 flash update

By Shared Research

  • Sales increased 1.7% YoY to JPY317.4bn, with net income rising 4,477.5% YoY due to extraordinary gains.
  • Operating profit rose 14.0% YoY, driven by improved production efficiency and higher supply volume despite rising costs.
  • Recurring profit increased 83.3% YoY, with significant foreign exchange loss reduction and higher interest and dividend income.

Oryzon Genomics — Progression across the pipeline in Q3

By Edison Investment Research

Oryzon Genomics has reported its Q325 results, a period characterised by tangible progress across its ongoing clinical programmes. Anticipation builds for vafidemstat in borderline personality disorder (BPD) following the receipt of feedback from the FDA for the proposed Phase III PORTICO-2 programme; interactions with the regulators have been constructive and Oryzon plans to resubmit a revised protocol. Oryzon’s oncology-haematology candidate, iadademstat, reported positive clinical data in acute myeloid leukaemia (AML) and further details are due to be presented at ASH 2025. We note that management aims to build the data package for iadademstat to support its efforts in seeking a partner, as part of a renewed strategy to become a central nervous system (CNS) specialist. Following the Q3 results, our valuation shifts to €909.3m or €11.4 per share (from €887.2m or €11.3 per share previously).


Seikagaku Corp (4548 JP): 1H FY03/26 flash update

By Shared Research

  • The company reported a sales decline of 11.4% YoY to JPY17.9bn, with an operating loss of JPY557mn.
  • Pharmaceuticals Business segment sales were JPY12.1bn, including JPY5.8bn in Domestic Pharmaceuticals and JPY4.4bn in Overseas Pharmaceuticals.
  • R&D expenses totaled JPY3.0bn (-6.7% YoY), representing 16.9% of sales excluding royalty income, with ongoing pipeline developments.

Ship Healthcare Holdings (3360 JP): 1H FY03/26 flash update

By Shared Research

  • Sales increased by 7.5% YoY to JPY333.4bn, with operating profit rising 5.6% YoY to JPY8.2bn.
  • Medical Supply segment sales grew 8.7% YoY, with a profit increase of 11.8% YoY to JPY2.8bn.
  • Ship’s FY03/26 forecast includes JPY700.0bn sales and JPY26.0bn operating profit, maintaining full-year targets.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief TMT/Internet: Softbank Group, Contemporary Amperex Technology (CATL), Giantec Semiconductor , Tekscend Photomask, Samsung Electronics Pref Shares, Broadex Technologies Co Ltd, Megaport Ltd, GDS Holdings (ADR), Monolithic Power Systems, Inc, Truecar Inc and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • Softbank Group: Performance Powered by OpenAI. Exits NVIDIA, Bets Big on AI
  • FXI Rebalance Preview: New Listings, Potential Inclusions, H/A Premiums
  • STAR Chip Index Rebalance Preview: One Change for December
  • TOPIX Inclusions: Who Is Ready (Nov 2025)
  • Clear Recent Outperformance of Korean Preferred Vs. Common Shares
  • ChiNext/​​​ChiNext50 Index Rebalance Preview: Maxing Out the Changes
  • Megaport Placement – Equity Raise Positioned for Scale and Global Expansion
  • LONG GDS: A High-Beta Asia Digital Infrastructure DC Operator
  • Monolithic Power Systems’ Bold Shift: From Chipmaker to Full Solution Powerhouse!
  • TrueCar’s Acquisition by Fair Holdings: Potential Returns, Funding Challenges


Softbank Group: Performance Powered by OpenAI. Exits NVIDIA, Bets Big on AI

By Devi Subhakesan

  • Softbank Group (9984 JP)  reported a record H1 net income of ¥2.9 trillion, driven principally by a USD 14.6 billion fair-value gain from its OpenAI investment and Rights to invest.
  • The Group fully exited its USD 2.9 billion NVIDIA Corp (NVDA US) stake in October, realizing gross gains of USD 2.9 billion on sale proceeds of USD 5.8 billion.
  • It also sold partial stakes in T-Mobile for USD 9.2 billion and Deutsche Telekom for USD 2.4 billion even as it raised its investment target in OpenAI to USD34.7 Bn.

FXI Rebalance Preview: New Listings, Potential Inclusions, H/A Premiums

By Brian Freitas

  • There could be 3 constituent changes for the iShares China Large-Cap (FXI) (FXI US) ETF in December. That could easily increase to 4.
  • Two of the forecast inclusions will also have inflows from the FGlobal Index at the same time, increasing the impact. The third is a potential HSCEI INDEX add in December.
  • The HA premiums for CATL (3750 HK) and Jiangsu Hengrui (1276 HK) have dropped ahead of lock-up expiry and there could be premium expansion closer to index/ETF inclusion.

STAR Chip Index Rebalance Preview: One Change for December

By Brian Freitas

  • There could be 1 constituent change for the STAR Chip Index at the December rebalance. There will also be a few capping changes.
  • Estimated one-way turnover is 2.3% resulting in a round-trip trade of CNY 2.5bn (US$352m). Passives need to trade between 0.3-0.4x ADV in the potential changes.
  • The forecast add and delete will have same-way flows from passive trackers of other indices and that will increase the impact on the stocks.

TOPIX Inclusions: Who Is Ready (Nov 2025)

By Janaghan Jeyakumar, CFA


Clear Recent Outperformance of Korean Preferred Vs. Common Shares

By Douglas Kim

  • In this insight, we provide reasoning behind the clear recent outperformance of Korean preferred shares versus common shares.
  • Among the 10 pairs, nine of them have preferred shares outperforming common shares in the past five days.
  • One of the main reasons why the preferred shares have recently outperformed their common counterparts is because of the expectation of the higher probability of lowering tax on dividends.

ChiNext/​​​ChiNext50 Index Rebalance Preview: Maxing Out the Changes

By Brian Freitas

  • With the review period complete, we forecast 10 changes for the ChiNext Index (SZ399006 INDEX) and 5 changes for the ChiNext 50 Index in December.
  • The largest flows will be in 2 stocks that are forecast adds for both indices. There are 14 stocks with over 0.5x ADV to trade from passive trackers.
  • The forecast adds outperformed the forecast deletes from June to August, but there has been significant underperformance since then. Outperformance could resume as positioning kicks in prior to announcement.

Megaport Placement – Equity Raise Positioned for Scale and Global Expansion

By Akshat Shah

  • Megaport Ltd (MP1 AU) is looking to raise around US$131m via a fully underwritten primary placement.
  • The company will use the proceeds to fund the acquisition of Latitude.sh and accelerate its network expansion into India.
  • In this note, we will talk about the deal dynamics and run the deal through our ECM framework.

LONG GDS: A High-Beta Asia Digital Infrastructure DC Operator

By Jacob Cheng

  • We like GDS holdings, a high-beta play on Asia data center market, on the back of strong AI and hyperscale cloud infra growth across Asia
  • GDS is a high beta play through 3 ways:  flexible capital deployment, high velocity AI growth, as well as diversification
  • We think AI growth and utilization may surprise on the upside.  Also, establishment of a C-REIT platform will enable asset recycling at a high multiple

Monolithic Power Systems’ Bold Shift: From Chipmaker to Full Solution Powerhouse!

By Baptista Research

  • Monolithic Power Systems Inc. (“the company”) in its third quarter of 2025, reported a banner quarter, achieving record revenue levels of $737.2 million, marking sequential growth of 10.9% and an 18.9% increase from the same period in the prior year.
  • This outcome underscores the efficacy of their diversified market approach and strategic innovations aimed at addressing specific customer needs across a variety of segments.
  • On a positive note, the company has demonstrated a robust capacity for growth, amplified by its successful penetration into multiple market segments.

TrueCar’s Acquisition by Fair Holdings: Potential Returns, Funding Challenges

By Special Situation Investments

  • TrueCar has signed a definitive agreement to be acquired by Fair Holdings for $2.55 per share in cash.
  • The acquisition deal is 72% funded, with Fair Holdings needing to raise an additional $60 million.
  • TrueCar’s past legal issues are unlikely to impact Fair’s fundraising efforts for the acquisition.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Light & Wonder , China Shengmu Organic Milk, Alibaba, Coca Cola Bottling Co. Consolidated, Sprouts Farmers Market, Eastroc Beverage Group, Hikari Tsushin, Ngk Spark Plug, FSN E-Commerce Ventures (Nykaa) and more

By | Consumer, Daily Briefs

In today’s briefing:

  • [Quiddity Index] Light & Wonder (LNW US/AU) US Delisting Event – Updating The Assumptions/Estimates
  • On China Shengmu (1432)’s Conditional MGO
  • Happy Singles’ Day! How Alibaba (9988 HK) And JD.com (9618 HK) Move After 11/11
  • The Viral Milk That Helped Set Off America’s Protein Boom
  • China Shengmu (1432 HK): Possible Offer, Potentially Problematic 50% Min Acceptance Condition
  • Sprouts Farmers Market Goes All-In on Health—Can Its Exclusive Products Win Big?
  • Pre-IPO Eastroc Beverage Group – The Outlook Is Not Optimistic, with More Valuation Decline Ahead
  • Hikari Tsushin (9435 JP): 1H FY03/26 Flash Update
  • Primer: Ngk Spark Plug (5334 JP) – Nov 2025
  • Nykaa’s Omnichannel Strategy Delivers Record Margins Amid Competitive Flux


[Quiddity Index] Light & Wonder (LNW US/AU) US Delisting Event – Updating The Assumptions/Estimates

By Travis Lundy

  • Light & Wonder (LNW US) will be delisted at the close of tomorrow US time (two trading days left) and shares converted to Australian CDIs.
  • After studying the matter we have amended our assumptions on how flows work. More net selling than expected in November, irksome uncertainy in December, more buyback flows in the meantime.
  • The stock was higher on earnings in Australia, skipped a day, then skipped another day, then jumped in the US yesterday. 

On China Shengmu (1432)’s Conditional MGO

By David Blennerhassett

  • On the 30th October, China Modern Dairy (1117 HK) (CMD) entered into a conditional SPA to acquire a 1.28% stake in raw milk producer China Shengmu Organic Milk (1432 HK) (CSM). 
  • CMD currently holds 29.99% in CSM. Should the SPA complete, CMD clears 30% and will be obligated to make an Offer for all shares not held. 
  • The Offer Price will be A$0.35/share, a 14.75% premium to undisturbed. The Offer will be conditional on a 50% acceptance hurdle. 

Happy Singles’ Day! How Alibaba (9988 HK) And JD.com (9618 HK) Move After 11/11

By Gaudenz Schneider

  • Alibaba (9988 HK) and JD.com (9618 HK) often see heightened volatility following Singles’ Day (11 November), though performance varies by year.
  • Alibaba’s post-event returns are mixed, averaging nearly twice its normal four-day move, while JD.com has shown stronger and more consistent gains.
  • Option markets imply elevated short-term volatility—especially for JD.com—with potential trading opportunities around the 14 November expiry.

The Viral Milk That Helped Set Off America’s Protein Boom

By Odd Lots

  • Introducing the all new Adobe Acrobat Studio with AI powered PDF spaces
  • Fairlife milk, a phenomenon in the dairy industry, known for being healthier and having longer shelf life
  • Protein craze in the beverage industry, highlighted by Fairlife and other protein drinks at Starbucks

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


China Shengmu (1432 HK): Possible Offer, Potentially Problematic 50% Min Acceptance Condition

By Arun George

  • On 30 October, China Modern Dairy (1117 HK) announced a conditional share purchase agreement to acquire 1.28% of outstanding China Shengmu Organic Milk (1432 HK) shares at HK$0.35 per share. 
  • The SPA is conditional on SAMR and independent CMD shareholder approval. SPA completion will trigger a mandatory conditional cash offer at HK$0.35 per share.
  • Post-Completion, CMD and concert parties will hold a 31.26% stake. The offer is conditional on a 50% minimum acceptance condition, which is problematic as the offer is not particularly attractive.  

Sprouts Farmers Market Goes All-In on Health—Can Its Exclusive Products Win Big?

By Baptista Research

  • Sprouts Farmers Market released a set of financial results for the third quarter of 2025 that presents a mixed picture for current and potential investors.
  • The company reported total sales of $2.2 billion, marking a 13% increase compared to the same quarter in the prior year.
  • Comparable store sales rose by 5.9%, indicating growth despite challenging market conditions.

Pre-IPO Eastroc Beverage Group – The Outlook Is Not Optimistic, with More Valuation Decline Ahead

By Xinyao (Criss) Wang

  • Based on 25Q3 results, the biggest problem lies in the continuous slowdown of its core business (energy beverages), which has led to the overall performance slightly falling short of expectations.
  • The upper limit of Eastroc Super Drink could be around RMB23-27 billion. Since energy beverages’ annual revenue has approached RMB16 billion, it’s becoming increasingly difficult to achieve the remaining growth.
  • The future growth of Eastroc may not support the current valuation. A more comfortable valuation range could be P/E of 20-25x, which will provide investors with sufficient margin of safety.

Hikari Tsushin (9435 JP): 1H FY03/26 Flash Update

By Shared Research

  • The company reported record highs for 1H with revenue of JPY361.7bn and profit attributable to owners of JPY70.3bn.
  • Effective Q1 FY03/25, the company adopted a new segmentation, now reporting seven segments, including Electricity and Gas.
  • Dividend forecasts for FY03/26 were raised to JPY736 per share, reflecting solid earnings and outlook adjustments.

Primer: Ngk Spark Plug (5334 JP) – Nov 2025

By αSK

  • NGK Spark Plug, now operating as Niterra, is the global leader in spark plugs and automotive sensors, commanding a dominant market share. However, the company faces a significant long-term structural headwind from the global transition to electric vehicles (EVs), which do not utilize its core products.
  • Management is actively pursuing a diversification strategy to mitigate EV risk, leveraging its core competency in ceramics to expand into higher-growth areas. Key focus areas include components for semiconductor manufacturing equipment, medical products, and next-generation technologies like solid-state batteries.
  • The company exhibits strong financial performance with consistent revenue growth, robust profitability, and significant cash flow generation. Valuation appears attractive relative to peers, but the market is pricing in the long-term uncertainty associated with the decline of the internal combustion engine (ICE).

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Nykaa’s Omnichannel Strategy Delivers Record Margins Amid Competitive Flux

By Sudarshan Bhandari

  • Nykaa delivered its strongest quarter in two years in Q2 FY26, with GMV up 30% YoY and EBITDA margins expanding 125 bps to 6.8%.
  • The results confirm that Nykaa’s profitability driven by owned brands, omnichannel integration, and AI-enabled personalization is firmly turning.
  • Fashion’s near-term breakeven and continued premiumization in beauty could re-rate Nykaa as a sustainable compounding story.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Financials: Dollar Index, JTC PLC, Aditya Birla Capital Ltd, Bajaj Finance Ltd, Bank Alfalah, NOK, Coinbase Global , Credit Suisse Group , Chiba Kogyo Bank, Punjab National Bank and more

By | Daily Briefs, Financials

In today’s briefing:

  • Global FX: Dollar oscillates; more fiscal clarity for GBP & CAD
  • Permira’s Recommended Cash Offer for JTC Plc
  • Aditya Birla Capital: Under-Appreciated Compounder or Value Trap?
  • Bajaj Finance: From Credit Tightening to Digital Acceleration – A Transition Year in Motion
  • Primer: Bank Alfalah (BAFL PA) – Nov 2025
  • European Rates: BoE and Scandi central bank roundup
  • Coinbase Is Quietly Building a Payments Powerhouse — The Untold Story Behind Its Expansion!
  • Primer: Credit Suisse Group (CSGN SW) – Nov 2025
  • Chiba Kogyo Bank (8337 JP): 1H FY03/26 flash update
  • Punjab National Bank (PNB IN) Vs. Bank of India (BOI IN): Quant-Driven Pair Trade in Indian Banks


Global FX: Dollar oscillates; more fiscal clarity for GBP & CAD

By At Any Rate

  • The US dollar remains strong despite ongoing government shutdown and uncertain economic data
  • Eurodollar shows resilience and potential for growth due to positive PMI data in Europe
  • Range-bound trading expected for Eurodollar with potential for upside breakout depending on US data and market conditions

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


Permira’s Recommended Cash Offer for JTC Plc

By Jesus Rodriguez Aguilar

  • Tight spread: JTC trades 1.7% below Permira’s 1,340p cash offer, implying a modest ~2% annualised return and ~94% market-implied completion probability.
  • Low risk: Fully financed, board-backed, minimal antitrust hurdles; interloper risk negligible after Warburg’s withdrawal.
  • Recommendation: Treat as cash-equivalent carry; lock in gains and redeploy to wider-spread, higher-return opportunities.

Aditya Birla Capital: Under-Appreciated Compounder or Value Trap?

By Sudarshan Bhandari

  • ABCL’s Q2 FY26 lending portfolio surged 29% YoY, driven by Housing Finance and secured MSME loans, while the firm deployed Generative AI across its flagship digital platforms.
  • Robust asset growth and an improving credit profile (Gross Stage 2 & 3 down 121 bps YoY in NBFC), but consolidated PAT growth was constrained by rising interest costs.
  • The One ABC’ digital ecosystem and high-growth segments position ABCL for enhanced return ratios, meriting a closer look at its valuation discount relative to pure-play NBFC peers.

Bajaj Finance: From Credit Tightening to Digital Acceleration – A Transition Year in Motion

By Sudarshan Bhandari

  • Company delivered a steady Q2 FY26, with PAT growth of 23% YoY and 4% QoQ, in line with expectations. MSME stress prompted a modest downgrade in AUM guidance to 22–23%
  • The quarter reflects the company’s pivot toward quality growth, fortified by an aggressive AI transformation program (FINAI) and gold loan expansion strategy.
  • While short-term credit costs weigh on margins, Bajaj Finance’s digital transformation and franchise scale position it to re-accelerate in FY27, reinforcing its premium valuation among Indian NBFCs.

Primer: Bank Alfalah (BAFL PA) – Nov 2025

By αSK

  • Bank Alfalah is demonstrating a strong growth trajectory, evidenced by significant year-on-year increases in revenue and net income, alongside a robust Capital Adequacy Ratio that is comfortably above regulatory requirements.
  • The bank is currently navigating short-term profitability pressures due to a high cost-to-income ratio, driven by branch expansion and a decline in remittance-related income. However, management anticipates a normalization of these costs.
  • Strategically, the bank is focused on enhancing its low-cost deposit base by improving its current account mix and is well-positioned to capitalize on the expected recovery in credit demand as interest rates become more favorable.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


European Rates: BoE and Scandi central bank roundup

By At Any Rate

  • Riksbank expected to stay on hold due to inflation moving along expected lines
  • Norges Bank has implicit easing bias but unlikely to deliver rate cuts based on incoming data
  • Bank of England keeps rates on hold with closer vote split, markets pricing in gradual rate cuts through early next year

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


Coinbase Is Quietly Building a Payments Powerhouse — The Untold Story Behind Its Expansion!

By Baptista Research

  • Coinbase Global Inc.’s Q3 2025 earnings reveal a mixed but strategically progressive narrative for the company.
  • With total revenue reaching $1.9 billion and adjusted EBITDA at $801 million, Coinbase demonstrates strong financial momentum, underpinned by the expansion of its “Everything Exchange” as announced in the previous quarter.
  • This initiative underscores Coinbase’s ambition to offer a single platform for trading diverse asset classes, beyond its traditional scope of cryptocurrencies.

Primer: Credit Suisse Group (CSGN SW) – Nov 2025

By αSK

  • Credit Suisse faced a terminal crisis of confidence following years of financial losses, risk management failures, and numerous scandals, culminating in its emergency acquisition by UBS in March 2023.
  • The government-brokered takeover by its historic rival UBS for CHF 3 billion was executed to prevent a wider systemic collapse, effectively ending Credit Suisse’s 167-year history as an independent institution.
  • The bank’s failure was rooted in a series of costly missteps, including massive losses from the collapses of Archegos Capital and Greensill Capital, which exposed deep-seated cultural and operational deficiencies.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Chiba Kogyo Bank (8337 JP): 1H FY03/26 flash update

By Shared Research

  • Consolidated ordinary income increased to JPY33.0bn (+15.7% YoY), with ordinary profit at JPY6.9bn (+16.0% YoY).
  • Non-consolidated core operating profit slightly declined to JPY6.0bn (-0.3% YoY), while ordinary profit rose to JPY6.8bn (+9.0% YoY).
  • The bank revised its FY03/26 forecast, projecting consolidated ordinary profit of JPY11.3bn (+5.8% YoY) and maintaining dividends.

Punjab National Bank (PNB IN) Vs. Bank of India (BOI IN): Quant-Driven Pair Trade in Indian Banks

By Gaudenz Schneider

  • Context: The Punjab National Bank (PNB IN) vs. Bank of India (BOI IN) price-ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.
  • Highlights: Going long Punjab National Bank (PNB IN) and short Bank of India (BOI IN) targets a 4% return.
  • Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: CNGR A/H Listing: Healthy A/H Premium and Cheap Valuation and more

By | Daily Briefs, ECM

In today’s briefing:

  • CNGR A/H Listing: Healthy A/H Premium and Cheap Valuation
  • CNGR Advanced Material H Share Listing (2579 HK): Valuation Insights
  • SHEIN Update: US$2 Bn Net, “Mid-Teens” Revenue Growth Targets Shared | New Challenges in France?
  • PhysicsWallah IPO: Driven by Passion to Educate; Sector Always in Controversy; No View on Valuation
  • Physicswallah IPO – RHP Updates and Thoughts on Valuation
  • Pre-IPO Immvira Bioscience – The Pipeline, the Concerns and the Valuation


CNGR A/H Listing: Healthy A/H Premium and Cheap Valuation

By Nicholas Tan

  • CNGR Advanced Material (300919 CH) is looking to raise up to US$500m in its upcoming Hong Kong IPO.
  • CNGR is a Chinese battery-component producer and a new energy materials company. It is the global leader of nickel-based and cobalt-based pCAM (cathode) for lithium-ion batteries.
  • In this note, we examine the IPO dynamics, and look at the firm’s valuation.

CNGR Advanced Material H Share Listing (2579 HK): Valuation Insights

By Arun George


SHEIN Update: US$2 Bn Net, “Mid-Teens” Revenue Growth Targets Shared | New Challenges in France?

By Daniel Hellberg

  • Reportedly, SHEN recently shared FY25 targets of US$2 bn Net, “mid-teens” sales growth
  • SHEIN faces familiar issues in France, where the company has just opened a physical store
  • The release of new FY25 financial targets suggest SHEIN is progressing towards an IPO 

PhysicsWallah IPO: Driven by Passion to Educate; Sector Always in Controversy; No View on Valuation

By Sreemant Dudhoria,CFA

  • Physicswallah Limited (2076103D IN) IPO opens today – 11 Nov 2025.The issue is a combination of fresh issue of INR 31 billion and offer for sale of INR 3.8 billion.
  • In this insight we discuss about the company, the industry, past controversies in the sector across major players.
  • We finally provide rationale why we do now know what valuation multiple to assign given the various factors.

Physicswallah IPO – RHP Updates and Thoughts on Valuation

By Sumeet Singh

  • Physicswallah Is looking to raise about US$434m in its upcoming India IPO.
  • Physicswallah Ltd (PWL) offers test preparation courses for competitive examinations, and other courses such as for upskilling, across 13 education categories, including JEE, NEET, and UPSC, among others.
  • We have looked at the company’s past performance in our earlier notes. In this note we talk about the RHP updates and provide our thoughts on valuations.

Pre-IPO Immvira Bioscience – The Pipeline, the Concerns and the Valuation

By Xinyao (Criss) Wang

  • The virus carrier process is complex.Cost of MVR-T3011 large-scale production is higher than antibody drugs.The awareness of oncolytic virus among doctors is insufficient. Market competition in engineered exosome is fierce.
  • As a clinical stage company, commercialization of its products is likely to seek business partners through a license-out model. So, how much sales/profit belongs to Immvira remains to be seen.
  • We think a neutral scenario is that valuation could be about US$10-1.2 billion. However, if the clinical data falls short of expectations, the valuation may be halved to US$500 million.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Thematic (Sector/Industry): Ohayo Japan | Shutdown Deal Nears and Tariff “Dividend” Pledge Boosts Optimism and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • Ohayo Japan | Shutdown Deal Nears and Tariff “Dividend” Pledge Boosts Optimism
  • Japan Morning Connection: Risk-On Mood Accelerates on AI and Tech Dip Buying
  • Singapore Market Roundup (10-Nov-2025): CGSI boosts DBS target price above $60, following Citi,
  • Thematic Report on The Great IT Bifurcation: Why TCS Is Downsizing While Coforge Soars


Ohayo Japan | Shutdown Deal Nears and Tariff “Dividend” Pledge Boosts Optimism

By Mark Chadwick

  • Wall Street surged on optimism over a Senate deal to end the US government shutdown, while President Trump promised Americans a $2,000 “dividend” funded by tariff revenues.
  • Tech stocks rebounded strongly, driving the Nasdaq up 2.2% near record highs, led by gains in NVIDIA (+5.8%), Palantir (+8.8%), and Micron (+6.5%).
  • Japanese stocks rose on Monday ahead of the Senate deal, with futures up further +0.7% on tech optimism, though upcoming SoftBank earnings may steer near-term sentiment.

Japan Morning Connection: Risk-On Mood Accelerates on AI and Tech Dip Buying

By Andrew Jackson

  • Takaichi loosening the investment spigots for nuclear and renewable will help the likes of JSW and Renova.
  • The European Commission banning ZTE and Huawei from telco networks will be a boon for NEC.
  • TSMC signalling 12 new leading edge fabs helps semi-caps outperforming, setting strong stage for Japan to start.

Singapore Market Roundup (10-Nov-2025): CGSI boosts DBS target price above $60, following Citi,

By Singapore Market Roundup

  • CGSI raises DBS target price above $60, joining Citi and Maybank.
  • RHB raises OCBC’s target price by 7% but remains ‘neutral’ post 3QFY2025 results.
  • RHB maintains DBS as ‘buy’ and UOB as ‘neutral’ after 3QFY2025 results.

Thematic Report on The Great IT Bifurcation: Why TCS Is Downsizing While Coforge Soars

By Nimish Maheshwari

  • Q2FY26 results show a “stabilizing” sector, but this was a illusion. The 30-90 bps margin beat was gifted almost entirely by a 3.6% INR depreciation.
  • The aggregate numbers hide a structural bifurcation. Tier-1 players like TCS face GenAI “productivity headwinds”, forcing “involuntary attrition”. Agile Mid-Tiers like Coforge and Persistent are monetizing AI and winning share.
  • Investors can no longer buy “the IT sector.” The Q2 results prove it’s a tale of two industries, a choice between leaders facing a painful transition and high-growth, high-premium challengers.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Event-Driven: On Jardine Matheson’s Latest Buyback and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • On Jardine Matheson’s Latest Buyback
  • Square’s Level 2 Leverage Caps End Tomorrow — Fresh Near‑term Factor in the Square Vs Hynix Setup
  • [Japan M&A] KKR and Founder to Take Engineer Staffing Agency Forum Engineering (7088) Private
  • Forum Engineering (7088 JP): KKR’s Tender Offer at JPY1,710
  • Weekly Update (Q, IAC, ANGI, LION, SNREY)
  • A/H Premium Tracker (Week to 7 Nov 2025):  Beautiful Skew Behaving Badly, CNOOC Better
  • Company Halts Operations, Initiates Strategic Review with Potential 50% Upside to Net Cash by Year-End
  • Kangji Medical (9997 HK): A Close Run Thing
  • Generation Bio’s Strategic Review: Potential 50% Upside Amid Restructuring and Cash Management Challenges


On Jardine Matheson’s Latest Buyback

By David Blennerhassett

  • On the 27th October, Jardine Matheson Holdings (JM SP) announced an Offer for 88.04%-held Mandarin Oriental International (MAND SP), after MAND concurrently announced the partial sale of OCB to Alibaba.  
  • MAND will pocket US$925mn from the sale. The privatisation will set Matheson back ~US$500mn. Alibaba is ostensibly funding MAND’s privatisation. And then some.  
  • Last week Matheson announced it will undertake a US$250mn buyback, which is expected to  complete in 2026.

Square’s Level 2 Leverage Caps End Tomorrow — Fresh Near‑term Factor in the Square Vs Hynix Setup

By Sanghyun Park

  • Square closed ₩290,000, missing all criteria; Level 2 removal effectively confirmed, with KRX disclosure expected ~8 p.m. Seoul, effective from tomorrow’s open.
  • Square vs Hynix hinges on retail chase structurally, but near‑term Square’s underperformance worsened by asymmetric leverage shackles.
  • Square’s Level 2 setup ends tomorrow; flows normalize, likely giving Square more juice vs Hynix. Key spot to watch from tomorrow’s open.

[Japan M&A] KKR and Founder to Take Engineer Staffing Agency Forum Engineering (7088) Private

By Travis Lundy

  • Today after the close, KKR announced a deal whereby they and founder OKUBO Izumi-san would take Forum Engineering Inc (7088 JP) private in an LBO. 
  • The process of this deal ticks most all of the “bad process” boxes but the price is pretty good.
  • 52% is locked in. Insiders and cross-holders appear to own another 15-18%. This looks like a done deal to me. Money comes 30 December.

Forum Engineering (7088 JP): KKR’s Tender Offer at JPY1,710

By Arun George

  • Forum Engineering Inc (7088 JP) has recommended a tender offer from KKR & Co (KKR US) at JPY1,710, a 32.6% premium to the last close price.
  • The offer is arguably light due to a lack of an auction and is below the midpoint of the target IFA DCF valuation range. 
  • However, the offer is attractive compared to precedent transactions, peer multiples and represents an all-time high. The large number of cross-holders will help meet the required tendering rate.

Weekly Update (Q, IAC, ANGI, LION, SNREY)

By Richard Howe

  • Dupont (DD) spin off its electronics business, Qnity (Q), early this week.

  • DQnity will be one of the world’s largest pure-play electronic materials companies, with a portfolio spanning semiconductor fabrication materials and advanced electronics/interconnect solutions.

  • Qnity’s Semiconductor Technologies division creates consumable products that are used during semiconductor manufacturing.

A/H Premium Tracker (Week to 7 Nov 2025):  Beautiful Skew Behaving Badly, CNOOC Better

By Travis Lundy

  • Beautiful Skew still AWOL/MIA. The wider the spread, the worse the result. 
  • Large SOE H vs A generally strong.  Strong net inflow into SOE Hs via SOUTHBOUND.
  • The data tables below update on a daily basis in the Tools section of Smartkarma. The SOUTHBOUND Flow Monitor and AH Pairs Monitor are both there – free – for all SK readers.

Company Halts Operations, Initiates Strategic Review with Potential 50% Upside to Net Cash by Year-End

By Special Situation Investments

  • The company has halted operations, laid off most staff, and initiated a strategic review with seven employees remaining.
  • Insiders, owning over 20% of shares, are incentivized to unlock value through liquidation, reverse merger, or sale.
  • A resolution from the strategic review is expected by year-end or early 2026, with ample margin of safety.

Kangji Medical (9997 HK): A Close Run Thing

By David Blennerhassett

  • 6.95%. That’s the key number at yesterday’s Scheme Meeting for Hangzhou Kangji Medical Instrument Co., Ltd. (9997 HK).
  • That’s still below the 10% blocking stake. But closer than the bankers and the market was anticipating. 
  • Arguably, the terms were therefore bang on. Last day of trading is today, with payment on the 16th December.

Generation Bio’s Strategic Review: Potential 50% Upside Amid Restructuring and Cash Management Challenges

By Special Situation Investments

  • Generation Bio’s net cash is projected at $7.6/share, 50% above the current price, with limited ongoing cash burn.
  • The company completed restructuring, retaining seven employees, and is considering liquidation, reverse merger, or sale options.
  • Major shareholders include Atlas Venture Life Science (12.4%), T. Rowe Price (12.6%), Moderna (8.7%), Fidelity (6.9%), and BlackRock (5.1%).

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Macro: CHINA’S AI COMMODITIZATION: Can Global AI Valuations Survive? and more

By | Daily Briefs, Macro

In today’s briefing:

  • CHINA’S AI COMMODITIZATION: Can Global AI Valuations Survive?
  • NPS Could Raise Allocation of Korean Stocks = KOSPI to 5,000 Soon
  • Oil futures: Crude recovers from lows, refining margins lift gloom
  • Poor Affordability and Structural Issues Take Their Toll on US Housing
  • Actinver Research – Consumer Post 3Q25 Update
  • Thailand Politics: Upcoming Polls Opens Window To Resolving Political Deadlock
  • Actinver Research – Real Estate Post 3Q25 Update
  • Asia base oils demand outlook: Week of 10 November
  • Asia base oils supply outlook: Week of 10 November
  • Malaysia’s Glove Sector Gradually Recovers Amid Trade Shifts


CHINA’S AI COMMODITIZATION: Can Global AI Valuations Survive?

By David Mudd

  • Chinese AI model downloads have surpassed those of the U.S. putting at risk the valuations of the large hyperscalers in the U.S.
  • Chinese open-source AI models offer a more secure, efficient, and lower cost alternative to Chat GPT -5 , Claude 4.5 Sonnet, and other U.S. LLMs.  
  • We believe that there will be a turning point when investors will realize that the Chinese open-source AI models have undercut the premise of U.S. global dominance of AI.

NPS Could Raise Allocation of Korean Stocks = KOSPI to 5,000 Soon

By Douglas Kim

  • One of the biggest stories in the Korean stock market in the past several weeks has been the discussions about NPS potentially increasing the allocation of Korean stocks.
  • If NPS announces a meaningful increase in the allocation of Korean stocks for its AUM, then there could certainly be an acceleration to KOSPI reaching 5,000. 
  • Based on what we have gathered so far, there is a higher probability (70-80%) that NPS meaningfully increases the allocation of Korean stocks in the next several months. 

Oil futures: Crude recovers from lows, refining margins lift gloom

By Quantum Commodity Intelligence

  • Crude oil futures nudged higher Friday but were heading for a second week of losses, albeit modest, with the market unable to shake off the gloom surrounding predictions of a massive oversupply in Q1.
  • Front-month Jan25 ICE Brent futures were trading at $63.72/b (2005 GMT) versus Thursday’s settle of $63.38/b, while Dec25 NYMEX WTI was at $59.84/b against a previous close of $59.53/b.
  • The oversupply narrative amid soaring supplies and tepid demand growth has taken hold of markets this week, overshadowing geopolitical concerns.

Poor Affordability and Structural Issues Take Their Toll on US Housing

By Said Desaque

  • Falling mortgage rates during 2025 have imparted a limited impact on housing activity.  Rates are higher than recent historic lows,  blunting channels through which lower mortgage rates benefit economic activity.
  • Poor affordability has been a headwind for housing in recent years., particularly since 2022. Rising home prices have made renting more affordable, notwithstanding supply shortages of desired housing stock.
  • Rising numbers of smaller households have boosted demand for smaller properties, but developers have been slow to respond to the shift by retaining a trading-up strategy in core urban areas.

Actinver Research – Consumer Post 3Q25 Update

By Actinver

  • In the midst of the soft top-line performance, management remains cautious, expecting more cost and Capex efficiencies, and a tough consumer environment with consumers remaining more selective as in previous quarters.
  • Still, most companies reiterated their FY25 guidance, with Bimbo an exception amid different FX conditions vs previously forecasted, and with Chedraui expecting downside risks at the top-line level.
  • Within Food & Bev, we continue to prefer AC, KOF, FEMSA and Becle (all Outperform). With no major PT changes, we continue to expect these players to outperform peers despite volume pressure and the excise taxes planned for next year. 

Thailand Politics: Upcoming Polls Opens Window To Resolving Political Deadlock

By Manu Bhaskaran

  • The once-tiny  Bhumjaithai Party has leveraged off shifting political dynamics such as the Pheu Thai Party’s decline to emerge as the most powerful power broker in the country. 
  • Hence, the coming election could break the 21-year old political deadlock by enabling a new political alignment that is better able to devise a fundamental political resolution. 
  • Such a resolution will allow a less distracted political class to tackle Thailand’s deep challenges, revive a moribund economy, and so escape the middle-income trap.

Actinver Research – Real Estate Post 3Q25 Update

By Actinver

  • We continue to observe mixed performance across our Real Estate coverage.
  • Industrial Real Estate companies once again delivered solid operational results —a trend we expect to persist— supported by ongoing development activity, and stable, inflation-linked revenues from their stabilized portfolios.
  • Despite continued uncertainty surrounding trade relations and tariffs, renewal rate growth remains robust across our covered names, while vacancy rates remain below 6%, underscoring the sector’s resilience.

Asia base oils demand outlook: Week of 10 November

By Iain Pocock

  • Asia’s base oils demand likely to stay muted.
  • Expectations of healthy availability of supply and seasonal slowdown in demand curb urgency to lock in additional volumes.
  • Seasonal slowdown could limit immediate impact of any adjustment in base oils output because of lower margins.

Asia base oils supply outlook: Week of 10 November

By Iain Pocock

  • Asia’s base oils prices extend steep fall vs gasoil prices.
  • Weaker outright prices compound the drop.
  • Sliding price-differentials, combined with increasingly firm diesel premium to crude oil, increase pressure on refiners to adjust output in response.

Malaysia’s Glove Sector Gradually Recovers Amid Trade Shifts

By Vinod Nedumudy

  • Glove demand rebounds as inventories normalize  
  • US tariffs boost Malaysian manufacturers’ market share  
  • Automation drives efficiency, supporting margin recovery

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: SK Square , LG Corp and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Square’s Level 2 Leverage Caps End Tomorrow — Fresh Near‑term Factor in the Square Vs Hynix Setup
  • LG Corp: NAV Analysis Suggests a 29% Upside, Likely to Catch Up to LG Chem


Square’s Level 2 Leverage Caps End Tomorrow — Fresh Near‑term Factor in the Square Vs Hynix Setup

By Sanghyun Park

  • Square closed ₩290,000, missing all criteria; Level 2 removal effectively confirmed, with KRX disclosure expected ~8 p.m. Seoul, effective from tomorrow’s open.
  • Square vs Hynix hinges on retail chase structurally, but near‑term Square’s underperformance worsened by asymmetric leverage shackles.
  • Square’s Level 2 setup ends tomorrow; flows normalize, likely giving Square more juice vs Hynix. Key spot to watch from tomorrow’s open.

LG Corp: NAV Analysis Suggests a 29% Upside, Likely to Catch Up to LG Chem

By Douglas Kim

  • Our updated NAV valuation of LG Corp suggests implied market cap of 17.2 trillion won or target price of 111,605 won per share, representing 29.3% higher than current levels.
  • LG Corp’s investment stakes in LG Chem and LG Electronics are worth 15.7 trillion won representing 119% of LG Corp’s entire market cap.
  • Lower taxes on dividends could accelerate the capital allocation to companies with higher dividend yields/payouts such as LG Corp.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars